Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 24:9:60.
doi: 10.21037/tgh-24-37. eCollection 2024.

A new era with advanced immunotherapy

Claudia Badia Lopez  1 , Elisabeth Ruijgrok  1 , Casper H J van Eijck  2   3
Affiliations
Editorial

A new era with advanced immunotherapy

Claudia Badia Lopez et al. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: AMPLIFY-201 trial; Kirsten rat sarcoma viral oncogene homolog (KRAS); immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-37/coif). C.H.J.v.E. reports that he had received consulting fees from AIM ImmunoTech Inc. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Pancreatic Cancer Prognosis 2024. Available online: https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreati...
    1. Conroy T, Castan F, Lopez A, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol 2022;8:1571-8. 10.1001/jamaoncol.2022.3829 - DOI - PMC - PubMed
    1. Brown CE, Hibbard JC, Alizadeh D, et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 2024;30:1001-12. 10.1038/s41591-024-02875-1 - DOI - PMC - PubMed
    1. Pant S, Wainberg ZA, Weekes CD, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med 2024;30:531-42. 10.1038/s41591-023-02760-3 - DOI - PMC - PubMed
    1. Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021;6:386. 10.1038/s41392-021-00780-4 - DOI - PMC - PubMed

LinkOut - more resources